Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing.

Chandrasekara, S; Lau, E M; Anderson, J; Collins, N; Cordina, R; Corrigan, C; Dwyer, N; Feenstra, J; Horrigan, Mark; Keogh, A; Kotlyar, E; Lavender, M; McWilliams, T; Rhodes, B; Steele, P; Strange, G; Thakkar, V; Weintraub, R; Whitford, H; Whyte, K; Williams, T; Wrobel, J; Keating, D T

doi:10.1016/j.hlc.2022.09.005

Title

Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing.

Publication Date

2023-02-08

Author(s)

Chandrasekara, S

Lau, E M

Anderson, J

Collins, N

Cordina, R

Corrigan, C

Dwyer, N

Feenstra, J

Horrigan, Mark

Keogh, A

Kotlyar, E

Lavender, M

McWilliams, T

Rhodes, B

Steele, P

Strange, G

Thakkar, V

Weintraub, R

Whitford, H

Whyte, K

Williams, T

Wrobel, J

Keating, D T

Subject

Calcium channel blockers

Pulmonary hypertension

Right heart catheter

Right ventricular failure

Vasoreactivity testing

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1016/j.hlc.2022.09.005

Abstract

Pulmonary arterial hypertension (PAH) has a progressive, unremitting clinical course. Vasoreactivity testing (VdT) during right heart catheterisation (RHC) identifies a subgroup with excellent long-term response to calcium channel blockade (CCB). Reporting on these patients is limited. Established in 2011, the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry offers the opportunity to assess the frequency of VdT during RHC, treatment and follow up of PAH patients.

Link

link

Citation

Heart, Lung and Circulation (2023) 32, 156–165

Jornal Title

Heart, Lung & Circulation

ISSN

1444-2892

Austin Health

Files: